19 Oct 2017 --- Researchers at the University of Alabama at Birmingham (UAB) have found a dietary combination that transforms the most lethal of all breast cancers into a highly treatable breast cancer. Specifically, scientists involved in the Scientific Reports study say sulforaphane – from cruciferous vegetables such as broccoli sprouts – along with polyphenols from green tea may be the key.

Epigenetics – the study of biological mechanisms that will switch genes on and off – are used by Trygve Tollefsbol, Ph.D., Professor of Biology in the College of Arts and Sciences and Senior Scientist at the Comprehensive Cancer Center and Yuanyuan Li, M.D., Ph.D., a Research Assistant Professor of Biology, as a mechanism to identify ways we can change human gene expressions in fatal diseases, including breast cancer.

All breast cancers are either estrogen receptor-positive (ER-positive) or estrogen receptor-negative (ER-negative), the UAB press release explains. The tumors in ER-negative breast cancer are much less likely to respond to hormone therapy than are tumors that are ER-positive, which means that ER-negative breast cancers are typically very aggressive.

“Unfortunately, there are few options for women who develop ER-negative breast cancer,” Tollefsbol says. “Because of the poor prognosis this type of cancer carries, new advances in prevention and treatment for ER-negative breast cancer have particular significance.”

“Eat your vegetables”: combining compounds
Tollefsbol and fellow researchers set out to further research how scientists can efficiently neutralize mechanisms that lead to, and worsen, ER-negative cancers. Up until now, conventional cancer prevention has focused primarily on single chemopreventive compounds.

“One reason many in the field shy away from combining two or more compounds at a time for treatment research is the fear of adverse effects and potential interactions that are unknown,” Tollefsbol says.

“To overcome that concern, we chose compounds that we felt confident would interact well together because they have similar favorable biological effects but still have different mechanisms for carrying out these effects that would not interfere with one another,” adds Tollefsbol.

Tollefsbol and his team identified two compounds in common foods that are known to have success in cancer prevention, and that could potentially be combined to successfully “turn on” the ER gene in ER-negative breast cancer so that the cancer could be treated with estrogen receptor inhibitors such as tamoxifen.

“One way we can use epigenetics as a powerful tool to fight cancer is through compounds found in our everyday diet,” Tollefsbol says. “Vegetables, for example, are filled with these types of compounds. Your mother always told you to eat your vegetables, and science now tells us she was right.”

Another compound found in green tea has been shown to stimulate epigenetic changes in cancerous genes, according to prior studies from Tollefsbol’s lab.

These compounds, used in the right way, can help modulate gene expression aberrations that are contributing to the disease.

The researchers found that a combination of dietary plant-derived compounds consisting of sulforaphane from cruciferous vegetables such as broccoli sprouts, along with polyphenols from green tea, is successful in preventing and treating ER-negative breast cancer in mice that are genetically programed to develop ER-negative breast cancer at high rates.

Further investigation revealed that the mechanism for the efficacy of these two dietary compounds involved epigenetic changes induced in the ER gene regulatory region.

With the combined dietary treatment the researchers administered, the tumors in the mice were converted from ER-negative to ER-positive cancers. This rendered the breast cancer easily treatable with tamoxifen, an estrogen receptor inhibitor.

“The results of this research provide a novel approach to preventing and treating ER-negative breast cancer, which currently takes hundreds of thousands of lives worldwide,” says Li. “The next step would be to move this to clinical trial, and to eventually be able to provide more effective treatment options for women either predisposed to or afflicted with this deadly disease.”